Presented by Eagle Tree Ventures: The biggest gains in venture investing happen long before the IPO. Accredited investors can access select private deals alongside top-tier venture firms — deal-by-deal, zero obligation. Fill out this form to request access.

A single late-stage trial result nearly doubled a stock before the bell, and the market repriced it on science alone, with no revenue timeline attached. Elsewhere, the beats got paid only modestly, though one long-running turnaround was finally rewarded for delivering something ordinary.

The punishment landed on anything tied to what people buy for their homes, where a guide-down and a trimmed outlook both said the second half looks harder than the quarter just reported. One crowded corner of the market also found out how little room a single penny leaves you.

Moderna (MRNA): +90%

The personalized cancer vaccine Moderna has been developing with Merck (MRK) posted positive results in a late-stage trial, and the stock soared before the bell. This is the validation the mRNA platform needed outside of infectious disease, which has been the entire bull case since the Covid revenue cliff faded. Neither company has said when it plans to file for approval in the US, so the market is pricing the science well ahead of the revenue.

Estee Lauder (EL): +13%

The beauty group beat on both lines in its fiscal fourth quarter and guided fiscal 2027 roughly in line with what analysts were modeling. For a turnaround that has spent two years underdelivering, in line is a win. The move says investors are ready to pay for stability again, not just for growth.

Analog Devices (ADI): +2%

The chipmaker beat on its fiscal third quarter and guided the current quarter above expectations, but the detail that matters is gross margin, which expanded meaningfully from a year ago. Analog's margins are one of the cleanest reads on whether the industrial and auto chip cycle has turned. Widening them while growing suggests pricing power is back.

Keysight Technologies (KEYS): +2%

The electronic test and measurement company cleared expectations on both the top and bottom lines in its third quarter. Keysight sells the instruments engineers use to design and validate new hardware, so its results tend to lead the broader tech spending cycle. A comfortable beat here is a quiet signal that engineering budgets are still open.

La-Z-Boy (LZB): -17%

The recliner maker guided current quarter revenue below what analysts were looking for, with first quarter earnings and operating income both down from a year ago. Big-ticket furniture is one of the purest reads on discretionary spending in retail, and this one is flashing weak. A drop this size on a guide-down says investors think the problem is the consumer, not the company.

Mercury Systems (MRCY): -9%

The defense and aerospace electronics maker guided fiscal 2027 revenue above the analyst consensus, but a fourth-quarter earnings miss of a single cent was enough to knock the stock down more than 9%. Defense electronics has been a crowded trade on the strength of the budget cycle, and crowded trades punish small misses hard. The reaction says more about positioning than execution.

Lowe's (LOW): -1%

The home improvement retailer cut its full-year sales and earnings outlook to the bottom end of its prior guidance, missed on second-quarter revenue, and pointed to pressure in home improvement spending. Homeowners locked into cheap mortgages are not moving, and that stalls the renovation cycle that drives this business. Guiding to the low end of a range you set yourself is the market's least favorite kind of confirmation.

Carvana (CVNA)

Retail traders have spent two sessions arguing about a shareholder rather than the business. Billionaire Mark Walter, who holds roughly 4% of the company, is under a federal investigation into his wider investment empire, and the market is worried he sells the stake to meet obligations elsewhere. StockTwits message volume has stayed elevated with sentiment parked in bearish territory, and the wallstreetbets threads have skewed heavily toward puts.

The stock fell on Monday and again on Tuesday for a two-day decline of more than 10%, on volume well above its 30-day average, and it was only mildly higher in early premarket trade. Nothing has actually been sold yet, so whether this resolves as a forced-seller overhang or an overreaction is the open question traders seem to be sizing up.

✌️That’s it for today.